University of California San Francisco (UCSF) news release
A new long-acting HIV treatment could expand options for people who have trouble taking daily pills and whose virus is resistant to some commonly used HIV drugs.
The only approved long-acting combination pairs cabotegravir with rilpivirine. But HIV can develop resistance to rilpivirine and related drugs, limiting its use for some people. Moreover, rilpivirine is not available in low- and middle-income countries.
The new approach replaces rilpivirine with lenacapavir, a long-acting drug that attacks HIV in a different way. In the new study, all the participants achieved and maintained control of the virus.
Read the full news release here.
Source : UCSF
Related HIV and Co-Infections News
-
Infectious Disease Advisor | Older age linked to better quality of life in adults with HIV after ART switch
-
LSE | New study finds major HIV service declines in Uganda and Zimbabwe after 2025 US aid cuts
-
[Press release] ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.